ID Care Research Bibliography

Infectious Disease Research

2023 & Earlier • 155 studies

Care Safety

2023

Yuen MF, Heo J, **Nahass R**, Wong G et al. Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection. EASL 2023 Vienna Austria.

2022

Sulkowski MS, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann HWL, Dieterich D, **Nahass RG**. Efficacy and safety of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection J Hepatology 2022. https://doi.org/10.1016/j.jhep.2022.05.027

Yuen MF, Agarwal k, Ma X,Nguyen TT, Schiff ER, Hann HWL, Dieterich DT, **Nahass RG.** Safety and efficacy of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection. https://doi.org/10.1016/j.jhep.2022.04.005 (doi: 10.1016/j.jhep.2022.04.005)

2020

Fung S, Sulkowski M, Lalezari J, Schiff E, Dieterich D, Hassanein T, Kwo R, Elkhashab M**, Nahass R**. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B. EASL 2020 London, England.

Impact Of Baseline Alanine Aminotransferase Levels On The Safety And Efficacy Of Remdesivir In Severe Covid-19 Patients, Aasld 2020

Jacobson IM, Ma X, Nguyen T, Schiff ER, Yuen MY, Hann HM, Sulkowski M, **Nahass R**, et al. Analysis Of Longer-Term Safety Profile Of The Hepatitis B Virus Core Inhibitor Abi-H0731 In An Open-Label Extension Study. AASLD 2020.

Yuen MF, Agarwal E, Ma X, Nguyen TT, Schiff E, Hann HW, Dieterich D, **Nahass R**, et al. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive chronic hepatitis B infection in a long-term extension study. EASL 2020. Virtual

Janssen H, Hou J, Asselah T, Chan H, Zoulim F, Tanaka Y, Janczewska E, Efficacy and **Nahass** RG, Safety Results of the Phase 2 JNJ-56136379 JADE Study in Patients with Chronic Hepatitis B: Interim Week 24 Data. EASL 2020. Virtual

2019

Ma X, Lalezari J, Nguyen T, Bae H, Schiff ER, Fung S, Yuen MF, Hassanein T, Hann HW , Elkhashab M, Dieterich D, Sulkowski M, Kwo P, **Nahass RG**, et al. Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients. EASL 2019, Amsterdam, Netherlands.

2018

Flamm SL, Cheng-Yuan P, Shibolet O, **Nahass R**, et al. Efficacy and Safety of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-Infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials. Gastro 2018

2017

Wedemyer H, Wyles D, Reddy R, Luetkemeyer A, Jacobson I, Vierling JM, Gordon S, **Nahass RG**. Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non- cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE). EASL, Amsterdam 2017

Safety and Efficacy of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials. AASLD 2017

FlammSL, Peng CY, Shibolet O, **Nahass RG**, et al. Safety and efficacy of 12 weeks of Elbasvir (EBR)/Grazoprevir (GSR) in Hepatitis C Virus (HCV) GT2- and GT4- infected participants 65 years and older: an integrated analysis of twelve clinical trials. AASLD 2017.

2016

Wyles D, Wedemeyer H, Reddy KR, Luetkemeyer A, Jacobson I, Vierling J, Gordon S, **Nahass R**, et al. Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE). AASLD, Boston 2016

2014

Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, **Nahass RG**, McNally J, Bainard DM et al. Safety and Efficacy of Treatment with the Interferon-free, Ribavirin-free combination of Sofosbuvir+GS-5816 for 12 Weeks in Treatment Naïve Patients with Genotype 1-6 HCV Infection. EASL, London UK 2014

Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, **Nahass** R, et al EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY. EASL, London, UK. 2014

Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, **Nahass R**. Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study. 65th Meeting of the American Association for the Study of Liver Diseases, Boston MA, 2014

2013

High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172/MK-8742 +/- RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study. AASLD 2013. Washington DC

K Patel, S Gordon, A Sheikh, Z Younes, J Ma, J McNally, DM Brainard, WT Symonds, JG McHutchison, **R Nahass**, EM Yoshida, H Reesink, D Nelson. Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data. AASLD 2013. Washington, DC

Keyur Patel, Stuart C. Gordon, Aasim M. Sheikh, Ziad Younes, Julie Ma, John McNally, Diana M. Brainard, William T. Symonds, John G. McHutchison, **Nahass RG**, Eric M. Yoshida, Hendrik W. Reesink, Nelson DR. Efficacy and Safety of Sofosbuvir in Patients According to Fibrosis Stage: An Analysis of Phase 3 Data. 64th Meeting of the American Association for the Study of Liver Diseases, Washington DC, 2013.

Lawitz E, Vierling J, Murillo A, Kugelmas M, Gerstoft J, Winkle P, Balart L, Christensen P, Ghalib R, **Nahass RG**, Shaughnessy M, Sun X, Hwang P, Wahl J, Robertson M, Haber B. High safety and efficacy of all oral combination regimen, MK 5172/MK 8742 +/- RBV for 12 weeks in HCV infected patients the C Worthy study. 64th Meeting of the American Association for the Study of Liver Diseases, Washington DC, abstract 76, 2013.

Clinical Disease Management

2023

Brunetti L, Chapy H, **Nahass RG**, Moore R, Wassef A, Adler D, Yurkow E, Kagan L. Relationship between Body Composition and Serum Immunoglobulin Concentrations after Administration of Intravenous Immune Globulin–Preclinical and Clinical Evidence. *Pharmaceutics*. 2023; 15(2):510. https://doi.org/10.3390/pharmaceutics15020510

Kohm K, Seneca K, Heineman D, Smith K, **Nahass RG**. Successful Treatment of *Cutibacterium acnes* Prosthetic Joint Infection with Single-Stage Exchange and Oral Antibiotics In Press OFID 2023

2022

San Filippo S, Crovetto B, Bucek J, **Nahass RG**, Milano M, MD,Brunetti L, PharmD, PhD, Comparative efficacy of early Covid-19 monoclonal antibody therapies: a retrospective analysis, *Open Forum Infectious Diseases*, 2022; ofac080, https://doi.org/10.1093/ofid/ofac080

Sulkowski MS, Fung SK, Ma X, Nguyen TT, Schiff ER, Hann HWL, Dieterich DT, **Nahass R**. Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B EASL 2022

2021

Nahass RG, Heinneman D, Seneca KJ. Successful Treatment of *Cutibacterium acnes* (CA) Prosthetic Device Infection (PDI) with Oral Linezolid and Rifampin (LR). **Nahass RG**, Esquivel M, Smith K, Heinemann D, Seneca KH, ID Week 2021. Virtual

Seneca KH, Homer R, **Nahass RG**. Treating Hepatitis C Virus (HCV) in Young Active Drug Users is Possible. ID Week 2021. Virtual.

Crovetto B, SanFilippo S, Milano M, Bucek J**, Nahass R**, Brunetti L. Does time from COVID-19 symptom onset to administration of anti-spike protein monoclonal antibody predict response? ID Week 2021. Virtual

2020

J Goldman, D Lye, D Hui, K Marks, R Bruno, R Montejano, Spinner CD, Galli M,Ahn M, **Nahass RG**, et al Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med (2020 May 27) DOI: 10.1056/NEJMoa2015301

Brunetti, L.; Diawara, O.; Tsai, A.; Firestein, B.L.; **Nahass, R.G**.; Poiani, G.; Schlesinger, N. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. *J. Clin. Med.* 2020, *9*, 2961

Hong TS, Gonzalez J, **Nahass RG**, Brunnetti L. Impact of hydroxychloroquine on mortality in hospitalized patients with COVID-19: systemic review and meta-analysis. Pharmacy 2020

Tsai, A., Diawara, O., **Nahass, R.G**. Brunetti L. Impact of tocilizumab administration on mortality in severe COVID-19. *Sci Rep* **10,** 19131 (2020).

Dalgard O, Litwin A, Dore G, Shibolet, Grebely J, **Nahass R**. Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR. EASL 2020. London England.

2019

Sulkowski MS, Agarwal K, Fung S, yuen MF, Ma X, Lalezari J, Nguyen TT, Bae H, Schiff ER, ... **Nahass RG**. Continued Therapy with ABI-H0731 + NrtI Results in Sequential Reduction/Loss of HBV DNA, HBV RNA, HBeAg, HBcrAg and HBsAg in HBeAg-Positive Patients. AASLD 2019. Boston MA.

2018

Poster Presentation: Decreasing Clostridium difficile Infection – One Hospital's experience: SHEA 2018 conference, Portland, OR

2017

Wyles D, Wedemyer H, Ben-Ari Z, Gane EJ, Hansen J, Jacobsen IM, Laursen B, Lautkmeyer A, **Nahass RG** et al. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure. HEPATOLOGY 2017;66:1794–1804)

Gane E, Metivier S, **Nahass RG**, et al. The Emergence of NS5B Resistance Associated Substitution S282T after Sofosbuvir-Based Treatment. J *Hepatology Communications* 2017;1:538–549.

2016

Miao B, Brunetti L, Bucek J, **Nahass R**; Increased Cardiac Risk With Concomitant Levofloxacin (LVQ) and Amiodarone (AMIO) Therapy, Open Forum Infectious Diseases, Volume 3, Issue suppl_1, 1 December 2016, 1981, https://doi.org/10.1093/ofid/ofw172.1529

Brunetti L, Bucek J, **Nahass, RG**. Increased Cardiac Risk With Concomitant Levofloxacin (LVQ) and Amiodarone (AMIO) Therapy. ID Week 2016. New Orleans.

2015

Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, Nahass RG, et al. Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes. Journal of Hepatology 62:S283 · March 2015

Brown RS, Puoti M, Cooper C, Wyles DL, Sepe TE, **Nahass RG,** et al. Implications of baseline HCV RNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-Week Treatement Outcomes. EASL, Vienna, Austria 2015.

Gane E, **Nahass RG**, Luketic V, et al. Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients **-** J Hepatology 2015;62:S621

Foster GR, Pianko C, Cooper,A Brown A,Forton D, **Nahass RG**, Sofosbuvir + PegInterferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic pacientes with genotype 2 HCV: The BOSON study. Hepatology 2015;62:S259-S260

Pol S, Sulkowski M, Hassanein T, Gane E, Liu L, Mo H, Doehle B, Kanwar B, Brainard D, Subramanian G, Symonds W, Mchutchinson J, **Nahass RG**, Bennett m, Jacobson I. Sofosbuvir plus peginterferon and ribavirin in patients with genotype 1 HCV in whom prior therapy with direct-acting antivirals has failed. Hepatology (in Press).

Massetto B,**Nahass RG**, et al. Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 and Treatment-Experienced Cirrhotic Patients with HCV Genotype 2. Gastro 2015

Gane E, **Nahass RG,** Luketic V, Hwang P, Robertson M, et al. Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in the treatment naive, noncirrhotic HCV genotype 3 infected patients. EASL, Vienna, Austria 2015.

Nelson M, Rockstroh J, Mallolas J, Katlama C, **Nahass RG**, et al. High efficacy of grazoprevir/elbasvir among HCV GT1, GT4, or GT6 infected patients with HIV Co Infection. ID Week 2015 San Diego, CA

2014

Marcellin P, Manns MP, Janczewska E, Muir AJ, Wu X, Trenkle D, Pang P, Kanawar B, Dvory-Sobol H, Subramanian M, McHutchison J, **Nahass RG**, Gordon SC, Jacobson IM. Ledispavir plus GS-9451 and PegIFN/RBV with high SVR12 rates in genotype 1 hepatitis C infection. NEJM 2014;370:1483-1493.

Sulkowski M, Mallolas J, Pol S, Bouliere M, Gerstoft, Shibolet O, **Nahass** R, et al. On treatment viral response of MK-5172/MK-8742 ± RBV for 12 weeks in HCV/HIV Co-Infected Patient Croi 2014

Markowitz M, **Nahass RG**, et al. Switch from NNRTI plus TVD to STB Maintains HIV Suppression and is Well- Tolerated. American Conference for Treatment of HIV, Denver 2014

Nahass RG, Vierling JM, Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients, by Baseline Demographics. ID Week 2014, Philadelphia PA.

Gregory Everson G,Sims K, Thuluvath P, Schwartz H, Hassanein T, Lawitz E, Webster L, Bräu N, Desta T, Galati J, Ghalib R, Gitlin N, Han S, Hinestrosa F, Rodriguez-Torres M, **Nahass R**, et al. Daclatasvir in combination with asunaprevir and BMS-791325 for prior null responders with chronic HCV genotype 1 infection. 65th Meeting of the American Association for the Study of Liver Diseases, Boston MA, 2014

2013

Patel S, Segal R, Brunetti L,Kalabalik J, **Nahass RG**. Effectiveness of a pharmacist managed vancomycin dosing protocol in achieving therapeutic levels in a Community Medical Center. IDSA 2013. San Francisco CA

2010

The clinical and prognostic importance of positive blood cultures in adults. Authors: Brian C Pien 1, Punidha Sundaram, Natalia Raoof, Sylvia F Costa, Stanley Mirrett, Christopher W Woods, L Barth Reller, Melvin P Weinstein. Am J Med. 2010 Sep;123(9):819-28. doi: 10.1016/j.amjmed.201 0.03.021.

2009

Discarding the initial aliquot of blood does not reduce contamination rates in intravenous-catheter-drawn blood cultures. Journal of Clinical Microbiology Volume 47 • Number 9 • September 2009. DOI: https://doi.org/10.1128/jcm.00292-09.
Sukrut Dwivedi, Rohit Bhalla, Donald R. Hoover, Melvin P. Weinstein

Clinical Trials

2022

Janssen HLA, Hou J, Asselah T, Chan HLY, Zoulim F, Tanakan Y, Janczewska E, **Nahass RG**, et al. A Randomized Phase 2 Study (JADE) of the HBV Capsid Assembly ModulatorNJ-56136379 With or Without a Nucleos(t)ide Analogue in Patients with Chronic Hepatitis B Infection. Gut 2023; 0:1–14. doi:10.1136/gutjnl-2022-328041In Press Gut

2020

Janssen H, Hou J, Asselah T, Chan H, Zoulim F, Tanaka Y, Janczewska E, **Nahass R**. Week 24 antiviral activity, safety and pharmacokinetics interim results of a phase 2 study of JNJ-56136379, a capsid assembly modulator, administered in combination with a nucleos(t)ide analogue in patients with chronic hepatitis B. EASL 2020, London, England.

2018

Winer B, Elham SD, Heath J, Katia G, Toettcher L, Huang T, Gerges S, Wiles M, Cullen J, Bram Y, Hrebikova G, Seneca K, **Nahass RG**. Preclinical assessment of antiviral therapy in a genetically humanized mouse model for persistent hepatitis delta virus infection. Sci Transl Med 2018

2017

Jacobson I, Lawitz E, Gane EJ, Willens BE, **Nahass RG**, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for 8 Weeks for Chronic HCV: Two Phase 3, Randomized Trials. Gastro 2017;153:113-122

Gane E, **Nahass RG,** Luketic V, Hwang P, Robertson M, et al., Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, non-cirrhotic HCV genotype 3-infected patients. J Hepatology 2017

Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, **Nahass RG**, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology. 2017 Jul;153(1):113-122)

2016

Dore GJ, Altice F,Litwin AH, Dalgard O, Gane EJ,Shibolet O, Luetkemeyer A, **Nahass R** et al. Elbasvir/Grazoprevir to Treat HCV Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Controlled Trial (C-EDGE CO-STAR). Annals of Int Med 2016:

Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy R, Tran T, Bennett M, **Nahass R**, Yang J, An D, Dvory-Sobol H, Stamm L, Brainard D, McHutchison J, et al. Sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection: an open-label, phase 2 trial, 2016 Jul 30. pii: S0016-5085(16)34835-1. doi: 10.1053/j.gastro.2016.07.039. [Epub ahead of print]

Lawitz E, Kowdley K, Curry M, Reau N, Nguyen M, Kwo P, Jacobson I, Tran T, **Nahass RG.** High efficacy of sofosbuvir/velpatasvir plus gs-9857 for 12 weeks in treatment-experienced genotype 1-6 hcv-infected patients, including those previously treated with direct-acting antivirals. EASL 2016 Barcelona Spain.

Nahass RG, et al. Sofosbuvir/Velpatasvir Plus GS-9857(100MG)for 6, 8, or 12 Weeks in Genotype 1-6 HCV-Infected Patients: An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies, ID Week 2016 New Orleans

Jacobson I, Asselah T, Nahass R, et al. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-naïve Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study. AASLD, Boston 2016

2015

Everson GT, Towner WJ, David MN, Wyles D, **Nahass RG**, et al. Sofosbuvir with velpatasvir in treatment-naive non-cirrhotic patients with genotype 1-6 hepatitis C virus infection: a randomized trial. Annals Int Med 2015; 163(11)

Foster GR, Pianko S, Cooper C, Brown A, Forton D, **Nahass RG**, et al. Sofosbuvir + PEGInterferon/Ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The Boson Study. EASL, Vienna 2015.

Kwo P, Gitlin N, Nahass RG, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (smv) plus sofosbuvir (sof) in treatment-naïve and -experienced patients with chronic hcv genotype 1 infection without cirrhosis: optimist-1. EASL, Vienna, Austria 2015.

2014

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, **Nahass R**, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir(MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2014; http://dx.doi.org/10.1016/S0140-6736(14)61793-1

Epidemiology

2022

Dalgard O, Litwin AH, Shibolet O, Grebely J, **Nahass R**, et al. Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection, Journal of Addictive Diseases 2022. DOI: 10.1080/10550887.2022.2088978

Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Ann Intern Med. 2022 Sep;175(9):1221-1229. doi: 10.7326/M21-4119. Epub 2022 Aug 9. PMID: 35939812.

Evaluation of Colorectal and Hip/Knee Arthroplasty Surgical Site Infections at Ocean University Medical Center. Open Forum Infectious Diseases, Volume 9, Issue Supplement_2, December 2022, ofac492.1061, https://doi.org/10.1093/ofid/ofac492.1061. Omar Ismail, PharmD, Yosef Nissim, PharmD, BCIDP, Nancy Kerr, RN, MSN, CIC, Thomas Lake, MD, Sukrut Dwivedi, DO, FACP

10/2022 Recurrence of Streptococcus agalactiae Bacteremia - Risk Factors and Complications. IDSA ID Week 2022

Serratia is a rare cause for Infective Endocarditis of the Tricuspid Valve. Samer I Talib, Nazar Raoof, Jonathan Kovacs, Natalia Raoof, Abdallah Khashan, Vasudev Daliparty, Srijana Poudel. *Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 1618, 2022*

Castleman disease, a dilemma in HIV patients: A clinical presentation and diagnostic approach. Samer Talib, Nazar Raoof

Rachel Cowan, Shruti Varadarajan, **Abraham Wei**, Tanzila Salim, Michelle DallaPiazza. Microbial perils of the tropics: A case of cutaneous leishmaniasis in an immigrant from South America. IDCases. 2022 Dec 31;31:e01669.

2021

Grebely J, Dore GJ, Altice FL, Conway E, Litwin AH, Norton,B, Dalgard O, Gane EJ, Shibolet O, **Nahass R**, et al. Reinfection and Risk Behaviors Following Treatment for Hepatitis C Virus Infection: the CO-STAR long term reinfection study. In press Annals of Internal Medicine

Flannery, S., Schwartz, R., Rasul, R., Hirschwerk, D. A., Wallach, F., Hirsch, B., & McGowan, J. (2021). A comparison of COVID-19 inpatients by HIV status. *International Journal of STD & AIDS*.

Khatri A., Malhotra P., Izard, S., Kim, A., Oppenheim, M., Gautam-Goyal, P., Chen, T., Doan, T., Berlinrut, I., Niknam, N., Flannery, S., Hirschwerk, D., Epstein, M., Farber, B. (2021). Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies. *Open Forum Infectious Diseases*, Volume 8, Issue 7, July 2021

06/2021 Hospital-acquired Bloodstream Infections in Patients Hospitalized with COVID-19: Association with Immunosuppressive Medications. Northwell Health Academic Day 2021

Yehuda Eidensohn, **Abraham Wei**, Michael Sirkin, Lisa L Dever. Brevibacteria tibial osteomyelitis. IDCases. 2021 Jan 12;23:e01046

Abraham Wei, Nehal Dhaduk, Basil Taha. Wrist abscess due to drug-resistant Pasteurella multocida. IDCases. 2021 Sep 2;26:e01277

2020

Shan Y, Dalal V, **Nahass R**, Rodricks M, Teichman A. Multi-System Inflammatory Syndrome in an Adult after COVID-19, IDCP Infectious Diseases in Clinical Practice: September 29, 2020 - Volume Publish Ahead of Print - Issue -doi: 10.1097/IPC.0000000000000938

Bhatt PJ, Shiau S, Brunetti L, Xie Y, Solanki K, Khalid S, Mohayya S, Au PH, Pham C, Uprety P, **Nahass R**, Narayanan N. Risk Factors and Outcomes of Hospitalized Patients with Severe COVID-19 and Secondary Bloodstream Infections: A Multicenter, Case-Control Study. Clin Infect Dis. 2020 Nov 20:ciaa1748. doi: 10.1093/cid/ciaa1748. Epub ahead of print. PMID: 33216875; PMCID: PMC7717183.

Mullan K, Criner G, Richterman AG, **Nahass RG**, et al. Racial/ethnic Disparities Not Observed in Clinical Outcomes with Remdesivir Treatment. International AIDS Society July 2020

2019

Seneca K, **Nahass RG**, Adler R. Burkitt Lymphoma presenting as fever of unknown origin and isolated hypoglossal nerve palsy. J Am Assoc Nurse Pract 2019 Aug 14.

Grebely J, Conway B, Litwin AH, Dalgard O, Shibolet O, **Nahass RG**, et al. Drug Use And Reinfection During And Following Hcv Treatment With Elbasvir/Grazoprevir (Ebr/Gzr) Among Patients Receiving Opioid Agonist Therapy: Final Results From The Co-Star Study. INHSU 2019, Montreal Canada.

Grebely J, Conway B, Litwin A, Dalgard O, Shibolet, Nahass R. Drug Use and Reinfection During and Following HCV Treatment With Elbasvir/Grazoprevir Among Patients Receiving Opioid Agonist Therapy: Final Results From the CO-STAR Study. AASLD 2019. Boston MA

2018

Parronchi CJ, Doshi V, **Nahass RG.** Histoplasmosis endophthalmitis – case report and review. Open Infect Dis J 2018:10:71-75.

Parker LR, Stanford B, **Nahass RG**. Hypertrophic Herpes Simplex – Pseudocarcinoma. Infect Dis Clin Pract 2018:

Grebely J, Litwin A, Dalgard O, Gane E, Shibolet, Conway B, Nahass R. HCV Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Patients on Opioid Agonist Therapy: Co-STAR Part B. AASLD 2018

Akyar E**,** Mora N, Luke A,Layden J,Phillips R, Agyarko-Poku T,Owusu,Helena D **Nahass RG**. Risk Factors for Hepatitis C in Western Africa: An Observational Study in an STI Clinic. ID Week 2018. San Fransisco

2017

Prevalence of Infection with Multiple Strains of Hepatitis C Virus (HCV) in Patients Enrolled in HCV Clinical Trials EASL Amsterdam 2017

Hepatitis C virus (HCV) reinfection and injection risk behavior following elbasvir/grazoprevir (EBR/GZR) treatment in patients on opioid agonist therapy (OAT): Co-STAR three-year follow-up study. DDW

Homer R, Seneca K, Schwartz M, Schofield N, **Nahass RG.** Characterization of Barriers to Successful Treatment of Hepatitis C in Young PWID's. ASAM 2017. New Orleans LA.

Nahass RG. HCV Reinfection and Injection Risk Behavior in Patients on Opioid Agonist Therapy. ASAM 2017. New Orleans, LA.

Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Conway B, **Nahass RG,** et al. Hepatitis C Virus reinfection and injecting risk behavior following elbasvir/grazoperevir treatment in participants on opiate agonist therapy: co-star part B. AASLD 2017

Isolated Streptococcus intermedius pulmonary nodules. Stephen Catalya, Bushra Komal, Sunil Tulpule, Nazar Raoof, Shuvendu Sen. *IDCases 8, 48-49, 2017*

2016

Brunetti L, Kagan L, Forrester G, Alexusnes L,**Nahass RG**. Cefoxitin plasma and subcutaneous adipose tissue concentration in patients undergoing sleeve gastrectomy. Clin Ther 2016 Jan 11;38(1):204-10.

Li Boning, Boretz R, **Nahass RG**. Thorn-Induced Alternaria septic arthritis and osteomyelitis of the hand. Infect Dis Clin Practice 2016;24:109-111. doi: 10.1097/IPC.0000000000000314

Akyar E, Seneca KH, Akyar S, Schoefield N, Schwartz MP, **Nahass RG**. Linkage to Care for Hepatitis C Virus (HCV) Among Suburban Heroin Users in New Jersey. Emerg Infect Dis 2016;22: DOI:10.3201/eid2205.151980

Dore GJ[1], Altice F[2], Litwin AH[3], Grebely J[1], Dalgard O[4], Gane E[5], Shibolet O[6], Luetkemeyer A[7], **Nahass R[8]**, et al. C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT). EASL 2016. Barcelona Spain.

Dore G, Grebely J, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, **Nahass R**, et al HCV reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR Three Year Follow-up Study. AASLD, Boston 2016.

SEPTIC ARTHRITIS: A Case of Haemophilus – Aggregatibacter Aphrophilus. American Journal of Infectious Diseases and Microbiology, 2016, Vol. 4, No. 4, 72-73. DOI:10.12691/ajidm-4-4-1. Muhammad Azharuddin, Lubna Bashir Munshi, Sukrut Dwivedi, Mark Anthony A. Diaz

Thoracic actinomycosis: A rare occurrence. Waqas Jehangir, Bhumesh Vaidya, Souad Enakuaa, Nazar Raoof, John R Middleton, Abdalla Yousif. *Infectious Disease Reports 8 (1), 5963, 2016*

Facial Cellulitis and Thrombosis With Pulmonary Septic Emboli Mimicking Lemierre's Syndrome. Sabrina Arshed, Mohammad Amir Hossain, Soaud Enakuaa, Sunil Tulpule, Qiang Nai, Mohammed Osman, Rafay Khan, Nazar Raoof, John Middleton, Purendu Sen, Abdalla Yousif. *Journal of Medical Cases 7 (3), 87-89, 2016*

2015

Nahass RG, C-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed Dose Combination (FDC) for 12 Weeks. INHSU 2015

Multi-organ failure secondary to a Clostridium perfringens gaseous liver abscess following a self-limited episode of acute gastroenteritis. Am J Case Rep. 2015; 16: 182–186. Published online 2015 Mar 25. doi: 10.12659/AJCR.893046. Sherif Ali Eltawansy, Chandni Merchant, Paavani Atluri, and Sukrut Dwivedi

Acute myocarditis secondary to Shigella sonnei gastroenteritis. JMM Case Reports (2015) DOI 10.1099/jmmcr.0.005000. Sherif Eltawansy, Paavani Atluri, Abhinav Agrawal, Sukrut Dwivedi and John Checton

Enteric fistulous communication with an aortobifemoral graft permitting for Eggerthella lenta colonization. Waqas Jehangir, Federico Sanabria, Zorawar Singh, Souad Enakuaa, Kebir Hammed Bedran, Nazar Raoof, Abdalla Yousif. *Journal of Global Infectious Diseases 7 (4), 170, 2015*

2014

HIV and aging: a clinical journey from Koch's postulate to the chronic disease model and the contribution of geriatric syndromes • Lisa M Chirch, Mohamed Hasham, George A Kuchel - *Current Opinion in HIV and AIDS 9 (4), 405-411, 2014*

Isolated left upper extremity myositis and severe rhabdomyolysis in an adult with H1N1 Influenza, a case report with literature review.
Αβηναω Αγραωαλ ετ αλ. ΙΔΧασεσ. 2014.

Acute confusional state: A manifestation of toxoplasma and CMV co-infection in HIV patient. Waqas Jehangir, Romil Sareen, Shuvendu Sen, Nazar Raoof, Abdalla Yousif. *North American journal of medical sciences 6 (10), 545, 2014*

2013

Nahass TA, Pittarelli L, McManus E, **Nahass RG.** The Greying of an Epidemic: A Descriptive Study of HIV in Patients over 70 Years of Age. ASM 2013. Denver, CO.

Nahass RG, Pittarelli L, Lafaro P, McDonough P. A Pseudo-epidemic of Tuberculosis Conversions Using Quantiferon Tb Gold In-tube (qft-git) for Testing High Risk Employees**.** ASM 2013. Denver, CO.

"Trends in Bacteroides Bacteremia," Poster Presentation, Infectious Diseases Society of America, 2013

2011

"Unusual Presentation of Eosinophilic Fasciitis," Poster Presentation, RWJMS Resident/Fellow Research Day 2011

2010

Gupta R, **Nahass RG.** Epidemiology of Candidemia in six community hospitals in New Jersey. Abstract 230. SHEA 2010. Atlanta, GA

Mathai, S., Bishburg, E., Slim, J. *et al.* Severe Malaria in Immigrant Population: A Retrospective Review. *J Immigrant Minority Health* **12**, 921–924 (2010). https://doi.org/10.1007/s10903-009-9256-5

2005

Nahass RG, Lafaro P. Increased number of deaths with a concomitant diagnosis of *C.difficile* in a community hospital. IDSA 2005

2003

Interpolation of Object Structure by the Human Visual System," Poster Presentation, Rutgers Undergraduate Research Day – 2003

Outbreak Management

2023

Abby Chopoorian, Padmapriya Banada, Robert Reiss, David Elson, Samuel Desind, Claire Park, Sukalyani Banik, Emily Hennig, Aanchal Wats, Austin Togba, **Abraham Wei**, Naranjargal Daivaa, Laura Palo, Mitchell Hirsch, Carter Campbell, Pooja Saiganesh, David Alland, Yingda L Xie. Persistence of SARS-CoV-2 in saliva: Implications for late-stage diagnosis and infectious duration. PLoS One. 2023 Mar 16;18(3):e0282708

2021

Nahass RG, McManus EJ. Unwinding Our COVID 19 Pandemic Safeguards After Vaccination. Biomed J Sci & Tech Res 35(5)-2021. BJSTR. MS.ID.005779

Nahass RG, Giordano A, McManus EJ. A Year with COVID19 – Experience from the Front Line in a Large Infectious Diseases Clinical Practice. ID Week 2021. Virtual

Parker L, Parillo S, **Nahass RG.** Investigation of a Clostridium difficile Infection (CDI) Outbreak in a Community Teaching Hospital. ID Week 2018. San Francisco.

2015

Nahass RG, et al. Hepatitis C Virus (HCV) In Young Suburban Heroin Users In New Jersey; Part Of The Second Wave Of Hepatitis C. ID Week 2015. San Diego, CA.

Seneca KJ, **Nahass RG.** Chikungunya Virus In New Jersey – Will We See a New Arbovirus Epidemic in the US? MDAdvisor Journal 2015 (in press)

2013

Boyanton BL Jr1, Almradi A2, Mehta T3, Robinson-Dunn B1. Performance of the directigen EZ Flu A +S rapid Influenza diagnostic test to detect pandemic influenza A/ H1N1 2009: Diagnostic Microbiology and Infectious Disease, 13 Oct 2013, 78(4): 360-362

2010

Tejal Mehta, Eric Mc Grath, Suchitha Bheemreddy, Hossein Salimnia, Nahed Abdel- Haq, Jocelyn Y. Ang, Lawerence Lum, Pranatharthi Chandrasekar, George J. Alangaden. Detection of Oseltamivir Resistance during Treatment of 2009 H1N1 Influenza Virus Infection in Immunocompromised Patients: Utility of Cycle Threshold Values of Qualitative Real-Time Reverse Transcriptase PCR. Journal of Clinical Microbiology.2010 Nov;48 (11):4326-4328

2007

Langer AJ, Lafaro P, Genese CA, McDonough P, **Nahass R**, Robertson C. Using active microbiologic surveillance and enhanced infection control measures to control an outbreak of health care-associated extended-spectrum beta-lactamase-producing *Klebisiella pneumonia* infections – New Jersey 2007. Am J Inf C 2009;37:73-75

Nahass RG, Lafaro P, McDonnough P. Screening for MRSA and Isolation of Patients with MRSA in A Community Hospital ICU Reduces Bacteremia. SHEA 2007

Stewardship

2021

Abraham E Wei, Ronald J Markert, Christopher Connelly, Hari Polenakovik. Reduction of central line-associated bloodstream infections in a large acute care hospital in Midwest United States following implementation of a comprehensive central line insertion and maintenance bundle. J Infect Prev. 2021 Sep;22(5):186-193.

2020

10/2020 COVID-19 Very High Clinical Likelihood Prediction Tool. IDSA ID Week 2020 - Virtual

2019

Eby J, Lane M, Horberg M, Gentry C, Coffin S, Ray A, Sheridan K, Bratzler D, Sarumi S, Wheeler D, Barlam T, Kim T, Rodriguez A, **Nahass RG.** How do you measure up. Quality measurement for improving patient care and establishing value for infectious diseases specialists. Clin Infect Dis 2019 05;68(11):1946-1951

Seneca K, Homer R, **Nahass RG**. Elimination of Hepatis C Virus (HCV) Requires Identification of Those Infected – A Successful Identification Process at Acute Detox Hospital. INHSU 2019, Montreal Canada.

2018

AASLD-IDSA HCV Guidance Panel **Nahass RG member**, Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection, *Clinical Infectious Diseases*, Volume 67, Issue 10, 15 November 2018, Pages 1477–1492, https://doi.org/10.1093/cid/ciy585

Poster Presentation: Collaborative Evaluation of Hospital-Onset C. difficile by Infection Prevention and Pharmacy via a Data Surveillance System : 6th Decennial International Conference on Healthcare Associated Infection: March 20, Atlanta, GA

Poster Presentation: So you want to Trial an Electronic Hand hygiene System? Lessons learned from Our Community Hospital's Experience: SHEA conference 2019, Boston, MA.

Is It Time to Assess the Role of Blood Cultures in the Current Practice of Medicine? Ali Nadhim, John R Middleton, Nazar Raoof, Iyengar Uma, Emily Tutino. *Open Forum Infectious Diseases 5 (Suppl 1), S552, 2018*

2017

Seneca K, Seyler N, Ferreira AM, Gerber F, Ahmed S, **Nahass RG.** Identify, Triage, and Treat (ITT) – A Programmatic Approach to the Assessment and Treatment of Patients with Clinical Changes to Limit Readmission. AMDA Phoenix 2017

Nahass RG, Seneca K, Seyler N. Successful Treatment of Bacteremia in the Post-Acute Setting – Another Opportunity to Limit Readmission. AMDA Phoenix 2017

2016

Muir A, Buti M, **Nahass R**, et al. Long-Term Follow-up of Patients with Chronic HCV Infection and Compensated or Decompensated Cirrhosis Following Treatment with Sofosbuvir-Based Regimens. AASLD, Boston 2016

2015

Brunetti L, Poustchi S, Cunningham D. Toscani M, Nguyen J, Lim J, Ding Y, Vigdor S, **Nahass RG.** Clinical and economic impact of empiric extended infusion piperacillin-tazobactam in a community medical center. Ann Pharmacotherapy Annals of Pharmacotherapy 2015;49(7)

2014

Nahass RG. Do clinical trials fit in private practice? Open Forum Infect Dis (Spring 2014)1(1)

Heinemann D, **Nahass RG**, Manno A. Innovations in Care to Provide Value in Healthcare Deliver Through Out-Patient Infusion Therapy. Association for Vascular Access, National Harbor MD 2014

2013

Nahass RG, Segal R, McDonnough P, Bollwage M, Brunetti L. Demonstrating Value For Antibiotic Stewardship Program (ASP) Through Cost Saving, Improved Antimicrobial Resistance Patterns And Stable Clinical Outcomes In A Community Hospital Setting Over A 3 Year Period. IDSA 2013. San Francisco CA.

2012

Boldt MD, Brill JV, Davis GL, Gordon SC, Kim AY, Kosinski LR, Levy AG, **Nahass RG**, Allen JI. Hepatitis C screening: Summary of recommendations from the clinical decision tool. Gastroenterology 2012;145:1146-1149.

The Value of the ID Doctor

2018

Infectious Diseases Specialty Intervention Is Associated With Better Outcomes Among Privately Insured Individuals Receiving Outpatient Parenteral Antimicrobial Therapy. Akshay Shah, Russell Petrak, Robert Fliegelman, Nabin Shrestha, Genève Allison, John Zurlo, Steven Parker, Donald Poretz, David McKinsey, Mark Dougherty, Lawrence Martinelli, Ajay Mathur, Andrés Rodriguez, Mark W Smith. Clinical Infectious Diseases, Volume 68, Issue 7, 1 April 2019, Pages 1160–1165, https://doi.org/10.1093/cid/ciy674 Published: 21 September 2018

2016

Nahass RG, Lafaro P, Parillo S, Moffa S, Brunetti L. Development of the Report Card for the Infectious Disease Service Line (IDSL). ID Week, New Orleans. 2016.

2015

Nahass RG. The infectious diseases physician in the future of healthcare; not only about antibiotic prescribing. CID 2015;60:773-776.

Nahass RG. The infectious disease service line. The next frontier in hospital/physician co-management. Phys Leadership J 2015;2:58-63.

Nahass RG. Infectious diseases manpower; a looming crisis. Infect Dis Clin Practice 2015;23:2223

2013

Schmitt S, McQuillen D, **Nahass RG**, et al. Infectious disease specialty intervention is associated with decreased mortality and lower healthcare costs. Clin Infect Dis 2013;57:1-7

2008

McQuillen DP, Petrak RM, Wasserman RB, **Nahass RG**, et al. The value of infectious diseases specialists: non – patient care activities. CID 2008;47:1051-1062.